高危CCUS与较低危MDS/肿瘤的临床与基因组趋同
这项前瞻性研究纳入409例CCUS和241例LR-MDS患者,采用统一诊断标准、集中病理审查和统一基因组分析,比较临床、分子及结局数据。以CHRS和CCRS分层,高危CCUS患者的临床特征和事件率与LR-MDS相当,而低/中危CCUS结局明显更好,支持保守管理。
要点
- CHRS或CCRS定义的高危CCUS临床特征与事件率与LR-MDS相当。
- 低/中危CCUS结局明显更好,支持保守管理。
- 部分高危CCUS与LR-MDS临床和基因组趋同,可考虑入组LR-MDS临床试验。
核心结论
- CHRS和CCRS是超越形态学分类的临床信息工具,支持对CCUS进行风险适应管理。
- 部分高危CCUS与LR-MDS临床和基因组趋同,支持考虑入组为LR-MDS设计的前瞻性临床试验。
研究设计与样本
- 前瞻性研究纳入409例CCUS和241例LR-MDS患者。
- 采用统一诊断和进展标准、集中病理审查及统一基因组分析。
- 使用CHRS和CCRS两个独立模型进行风险分层。
主要发现
- CHRS或CCRS定义的高危CCUS临床特征和事件率与LR-MDS相当。
- 低或中危CCUS结局明显更好,支持保守管理。
- 部分高危CCUS与LR-MDS显示显著临床和基因组趋同。
关键数值与推荐
- CCUS定义为不明原因血细胞减少伴髓系相关体细胞突变,但不满足MDS诊断标准。
- 当前CCUS与LR-MDS的临床区分主要依赖半定量形态学阈值。
临床怎么用
- 使用CHRS和CCRS对CCUS进行风险分层,高危者按LR-MDS模式管理。
- 低/中危CCUS可考虑保守管理。
- 部分高危CCUS可考虑入组为LR-MDS设计的前瞻性临床试验。
局限性
- 需进一步研究该人群的风险适应治疗策略。
- 强调前瞻性临床评估的重要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clonal cytopenia of undetermined significance (CCUS) is defined by unexplained cytopenias with myeloid-associated somatic mutations not meeting diagnostic criteria for myelodysplastic syndromes/neoplasms (MDS) yet carries a highly risk-stratified probability of progression to myeloid neoplasms. The clinical distinction between CCUS and lower-risk MDS (LR-MDS) is challenging because current criteria rely heavily on semi-quantitative morphologic thresholds, despite substantial clinical and molecular overlap. In this prospective study of 409 patients with CCUS and 241 with LR-MDS, we applied harmonized diagnostic and progression criteria, rigorous centralized pathology review, and uniform genomic profiling to compare clinical, molecular, and outcome data. Risk stratification was performed using two independent models-the Clonal Hematopoiesis Risk Score (CHRS) and the Clonal Cytopenia Risk Score (CCRS). Patients with high-risk CCUS, as defined by CHRS or CCRS, exhibited clinical features and event rates comparable to those with LR-MDS. In contrast, patients with low- or intermediate-risk CCUS had markedly improved outcomes, supporting conservative management. These findings underscore that CHRS and CCRS are clinically informative tools that extend beyond morphology-based classification and enable a risk-adapted approach to the management of CCUS. Importantly, a subset of patients with high-risk CCUS demonstrated substantial clinical and genomic convergence with LR-MDS, supporting their consideration for enrollment in prospective clinical trials designed for LR-MDS. These observations highlight the need for further study of risk-adapted therapeutic approaches in this population and underscore the importance of prospective clinical evaluation.
引用
- Xie Z, Komrokji ZR, Otterstatter M, et al. Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms. Blood. 2026. PMID: 42526047. doi:10.1182/blood.2026033085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。